MorphoSys to develop GM-CSF inhibitors for RA

German biotechnology company MorphoSys AG has disclosed the target of its developmental rheumatoid arthritis treatment, MOR103. The drug, a fully-human antibody, is designed to interact with the granulocyte macrophage-colony stimulating factor cytokine, and thereby reduce the level of damaging inflammation associated with the condition.

MorphoSys also announced that it has signed a deal with the University of Melbourne, Australia, under which it has gained exclusive access to rights to the use of GM-CSF inhibitors in autoinflammation, covered by pending US patent applications. The Martinsreid-headquartered firm said that, if the University's patents are approved, its agreement will provide it with market exclusivity for the use of GM-CSF targeting antibodies in anti-inflammatory indications in the USA.

Under the terms of the deal, the University will receive an upfront fee as well as milestone payments based on the achievement of developmental and regulatory goals. MorphoSys, which applied to conduct Phase I trials of MOR103 in December last year, has also agreed to pay royalties on net US sales of the product if it is successfully commercialized.